Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Thrombomodulin expressing monocytes are associated with low risk features in myelodysplastic syndromes and dampen excessive immune activation.

van Leeuwen-Kerkhoff N, Westers TM, Poddighe PJ, de Gruijl TD, Kordasti S, van de Loosdrecht AA.

Haematologica. 2019 Jul 4. pii: haematol.2019.219303. doi: 10.3324/haematol.2019.219303. [Epub ahead of print]

2.

Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lubbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstocker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 May 2. pii: haematol.2019.222059. doi: 10.3324/haematol.2019.222059. [Epub ahead of print]

3.

The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?

van Spronsen MF, Westers TM, Lissenberg-Witte BI, Wondergem M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2019 Apr 19. pii: haematol.2018.212563. doi: 10.3324/haematol.2018.212563. [Epub ahead of print]

4.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ, Vellenga E, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10.

PMID:
30630862
5.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3. Epub 2018 Dec 12.

PMID:
30542144
6.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S.

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7. Review.

PMID:
30404811
7.

Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands.

Kalin B, Pijnappel EN, van Gelder M, Visser O, van de Loosdrecht AA, Ossenkoppele GJ, Cornelissen JJ, Dinmohamed AG, Jongen-Lavrencic M.

Cancer Epidemiol. 2018 Dec;57:90-96. doi: 10.1016/j.canep.2018.09.007. Epub 2018 Oct 20.

PMID:
30347337
8.

TCF4 promotes erythroid development.

In 't Hout FEM, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, Jansen JH, Huls G.

Exp Hematol. 2019 Jan;69:17-21.e1. doi: 10.1016/j.exphem.2018.10.002. Epub 2018 Oct 10.

PMID:
30315825
9.

Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes.

Ping Z, Chen S, Hermans SJF, Kenswil KJG, Feyen J, van Dijk C, Bindels EMJ, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EMP, Lindenbergh-Kortleve DJ, Samsom JN, van de Loosdrecht AA, Raaijmakers MHGP.

Leukemia. 2019 Feb;33(2):536-541. doi: 10.1038/s41375-018-0267-x. Epub 2018 Oct 12. No abstract available.

10.

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes.

Duetz C, Westers TM, van de Loosdrecht AA.

Pathobiology. 2019;86(1):14-23. doi: 10.1159/000490727. Epub 2018 Sep 18. Review.

11.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

12.

Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ Non-Classical Monocytes.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, Lindstedt M, de Gruijl TD, van de Loosdrecht AA.

Front Immunol. 2018 Jul 16;9:1619. doi: 10.3389/fimmu.2018.01619. eCollection 2018.

13.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

14.

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP.

Leukemia. 2018 Aug;32(8):1679-1696. doi: 10.1038/s41375-018-0173-2. Epub 2018 Jun 26. Review.

PMID:
29946191
15.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

16.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

17.

MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands.

Dinmohamed AG, Visser O, Posthuma EFM, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M.

Cancer Epidemiol. 2017 Oct;50(Pt A):137-140. doi: 10.1016/j.canep.2017.08.016. Epub 2017 Sep 11.

PMID:
28910695
18.

Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes.

van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, van de Loosdrecht AA.

Am J Hematol. 2017 Nov;92(11):E631-E634. doi: 10.1002/ajh.24867. Epub 2017 Aug 24. No abstract available.

19.

Transcriptional profiling reveals functional dichotomy between human slan+ non-classical monocytes and myeloid dendritic cells.

van Leeuwen-Kerkhoff N, Lundberg K, Westers TM, Kordasti S, Bontkes HJ, de Gruijl TD, Lindstedt M, van de Loosdrecht AA.

J Leukoc Biol. 2017 Oct;102(4):1055-1068. doi: 10.1189/jlb.3MA0117-037R. Epub 2017 Jul 18.

PMID:
28720687
20.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L.

Int J Mol Sci. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837.

21.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
22.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

23.

Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Witte BI, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2017 Feb;72:269-271. doi: 10.1016/j.ejca.2016.11.029. Epub 2017 Jan 2. No abstract available.

PMID:
28057399
24.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

25.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.

26.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

27.

Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.

Zambetti NA, Ping Z, Chen S, Kenswil KJG, Mylona MA, Sanders MA, Hoogenboezem RM, Bindels EMJ, Adisty MN, Van Strien PMH, van der Leije CS, Westers TM, Cremers EMP, Milanese C, Mastroberardino PG, van Leeuwen JPTM, van der Eerden BCJ, Touw IP, Kuijpers TW, Kanaar R, van de Loosdrecht AA, Vogl T, Raaijmakers MHGP.

Cell Stem Cell. 2016 Nov 3;19(5):613-627. doi: 10.1016/j.stem.2016.08.021. Epub 2016 Sep 22.

28.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

29.

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D.

Blood. 2016 Oct 20;128(16):2096-2097. doi: 10.1182/blood-2016-07-728766. Epub 2016 Aug 17. No abstract available.

30.

Time-dependent changes in mortality and transformation risk in MDS.

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Levis A, Luebbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SM, Miyazaki Y, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Blood. 2016 Aug 18;128(7):902-10. doi: 10.1182/blood-2016-02-700054. Epub 2016 Jun 22.

31.

Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.

Dinmohamed AG, van Norden Y, van de Loosdrecht AA, Jongen-Lavrencic M.

Leukemia. 2016 Aug;30(8):1795-6. doi: 10.1038/leu.2016.117. Epub 2016 May 20. No abstract available.

PMID:
27198054
32.

Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs.

Chen S, Zambetti NA, Bindels EM, Kenswill K, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EM, Westers TM, Jansen JH, van de Loosdrecht AA, Raaijmakers MH.

Leukemia. 2016 Sep;30(9):1938-42. doi: 10.1038/leu.2016.91. Epub 2016 Apr 25. No abstract available.

33.

Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.

van Spronsen MF, Ossenkoppele GJ, Westers TM, van de Loosdrecht AA.

Eur J Cancer. 2016 Mar;56:10-20. doi: 10.1016/j.ejca.2015.12.004. Epub 2016 Jan 19.

PMID:
26798967
34.

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.

Ossenkoppele GJ, Janssen JJ, van de Loosdrecht AA.

Haematologica. 2016 Jan;101(1):20-5. doi: 10.3324/haematol.2015.139105. Review.

35.

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

Cremers EMP, Westers TM, Alhan C, Cali C, Wondergem MJ, Poddighe PJ, Ossenkoppele GJ, van de Loosdrecht AA.

Eur J Cancer. 2016 Feb;54:49-56. doi: 10.1016/j.ejca.2015.11.013. Epub 2015 Dec 22.

PMID:
26720403
36.

Apoptotic vesicles as tumor vaccine.

Horrevorts SK, Garcia-Vallejo JJ, van Vliet SJ, van de Loosdrecht AA, van Kooyk Y, de Gruijl TD.

Immunotherapy. 2016;8(1):5-8. doi: 10.2217/imt.15.96. Epub 2015 Dec 7. No abstract available.

PMID:
26641072
37.

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.

Alhan C, Westers TM, Cremers EM, Cali C, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2016 Jul;90(4):358-67. doi: 10.1002/cyto.b.21333. Epub 2015 Dec 14.

38.

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Leukemia. 2016 Mar;30(3):658-65. doi: 10.1038/leu.2015.295. Epub 2015 Oct 27.

PMID:
26503643
39.

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M.

Leukemia. 2015 Dec;29(12):2449-51. doi: 10.1038/leu.2015.220. Epub 2015 Sep 15. No abstract available.

PMID:
26369829
40.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Ruben JM, Visser LL, Heinhuis KM, O'Toole T, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

PLoS One. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219. eCollection 2015.

41.

Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Cancer Immunol Immunother. 2015 Nov;64(11):1419-27. doi: 10.1007/s00262-015-1741-1. Epub 2015 Jul 28.

42.

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.

Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17.

PMID:
26183645
43.

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

van Luijn MM, van den Ancker W, van Ham SM, van de Loosdrecht AA.

Oncoimmunology. 2015 Jan 7;3(12):e941737. eCollection 2014 Dec.

44.

Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012.

Dinmohamed AG, Brink M, Visser O, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M, de Greef GE.

Br J Haematol. 2015 Nov;171(3):436-9. doi: 10.1111/bjh.13414. Epub 2015 Apr 8. No abstract available.

PMID:
25854120
45.

Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2015 Jun;100(6):e220-2. doi: 10.3324/haematol.2014.116657. Epub 2015 Mar 6. No abstract available.

46.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
47.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Cremers EM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA.

Best Pract Res Clin Haematol. 2015 Mar;28(1):14-21. doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11. Review.

PMID:
25659726
48.

In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Ruben JM, Bontkes HJ, Westers TM, Hooijberg E, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Oncoimmunology. 2014 Jul 3;3(7):e946360. eCollection 2014.

49.

Granulomatous lung disease in a patient with a family history of hematological disorders.

Overbeek MJ, van de Loosdrecht AA, Vonk-Noordegraaf A.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):350-3.

PMID:
25591147
50.

The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.

Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M.

Leuk Res. 2015 Feb;39(2):177-82. doi: 10.1016/j.leukres.2014.11.025. Epub 2014 Dec 4.

PMID:
25533930

Supplemental Content

Loading ...
Support Center